Novel Organoid Matrix Enables Long-Term Culture of Human Hepatocytes
AMSBIO reports on the recent publication in Cell by Dr Meritxell Huch, Prof Hans Clevers et al. of ground-breaking research using Cultrex BME2 reduced growth factor (organoid growth matrix) to enable long-term (>1 year) culture of genome-stable bipotent stem cells from adult human liver. These results open up new experimental avenues towards the use of human liver material expanded in vitro as an alternative cell source for disease modeling, toxicology studies, drug testing, regenerative medicine and gene therapy.
Liver diseases (ranging from genetic inherited disorders to viral hepatitis, liver cancer, and obesity-related fatty liver disease) are the twelfth-leading cause of death in the US. Failure in the management of liver diseases can be attributed to the shortage of donor livers as well as to our poor understanding of the mechanisms behind liver pathology. The value of any cultured cell as a disease model or as a source for cell therapy transplantation depends on the fidelity and robustness of its expansion potential as well as its ability to maintain a normal genetic and epigenetic status.
The research by Huch, Clevers et al. shows that primary human bile duct cells can readily be expanded in vitro as bipotent stem cells into 3D liver organoids using AMSBIO’s reduced growth factor basement membrane extract Cultrex BME2 as extracellular matrix (ECM). In this novel culture system, adult liver stem cells maintain their ability of self-renewal; differentiating into functional hepatocyte cells in vitro and generating bona fide hepatocytes upon transplantation. Extensive analysis of the genetic stability of cultured organoids in vitro demonstrates that the expanded cells preserve their genetic integrity over months in culture (agreeing with the authors’ previous observations in a mouse model). Organoids derived from patients with genetic disorders can be used to model liver disease in vitro.
Commenting on this research, Dr Huch said “We have obtained culture conditions that allow us to long-term expand genetically stable human donor liver cells in organoid culture. One of the clues to this success is the use of ECM that allows the cells to grow in 3D. BME2 has been our ECM of choice for these experiments.”
AMSBIO has been working with the variability of the cellular microenvironment and how it affects the physiological relevance of cell culture. Factors contributing to this variability include: organ specific stromal cells, growth factors, proteoglycan and protein composition, and stiffness or tensile strength of the basement membrane extract or extracellular matrix. Matrices from AMSBIO not only support cells and cell layers, but also play an essential role in tissue organization that affects cell adhesion, migration, proliferation, and differentiation. These aspects can be studied with kits from AMSBIO incorporating their wealth of experience in this area. Cultrex Basement Membrane Extract (BME) is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumour. The extract gels at 37 °C to form a reconstituted basement membrane. Major components of BME include laminin, collagen IV, entactin, and heparan sulfate proteoglycan. These extracted proteins can be used in multiple applications, under a variety of cell culture conditions, for maintaining growth or promoting differentiation of primary endothelial, epithelial, smooth muscle and stem cells. BME can also be utilized in cell attachment, neurite outgrowth, angiogenesis, in vitro cell invasion and in vivo tumorigenicity assays. The new BME 2 is a proprietary formulation that has a higher tensile strength than similar products such as Matrigel.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance